Table 2.
Cancer type | Characteristic | Total (cases) | HR (95% CI) | P |
---|---|---|---|---|
BRCA | Age (years) | |||
≤ 60 | 96 | 1.000 | ||
> 60 | 49 | 1.467 (0.864–2.752) | 0.323 | |
TNBCa | ||||
No | 109 | 1.000 | ||
Yes | 24 | 2.296 (1.169–4.508) | 0.016 | |
TNM stageb | ||||
I/II | 95 | 1.000 | ||
III/IV | 48 | 2.296 (1.279–4.120) | 0.005 | |
PGK1 pS203 | ||||
Low | 65 | 1.000 | ||
High | 80 | 1.905 (1.024–3.546) | 0.042 | |
PDHK1 pT338 | ||||
Low | 66 | 1.000 | ||
High | 79 | 1.969 (1.058–3.665) | 0.032 | |
LIHC | Age (years) | |||
≤ 60 | 75 | 1.000 | ||
> 60 | 110 | 1.351 (0.863–1.962) | 0.527 | |
Gender | ||||
Male | 159 | 1.000 | ||
Female | 26 | 0.597 (0.327–1.087) | 0.092 | |
TNM stagec | ||||
I/II | 73 | 1.000 | ||
III/IV | 104 | 2.796 (1.848–4.229) | < 0.001 | |
PGK1 pS203 | ||||
Low | 107 | 1.000 | ||
High | 78 | 1.909 (1.311–2.781) | 0.001 | |
PDHK1 pT338 | ||||
Low | 105 | 1.000 | ||
High | 80 | 2.354 (1.610–3.441) | < 0.001 | |
LUAD | Age (years) | |||
≤ 60 | 84 | 1.000 | ||
> 60 | 95 | 1.339 (0.944–1.900) | 0.102 | |
Gender | ||||
Male | 104 | 1.000 | ||
Female | 75 | 0.775 (0.542–1.107) | 0.162 | |
TNM stage | ||||
I/II | 105 | 1.000 | ||
III/IV | 74 | 1.861 (1.309–2.647) | 0.001 | |
PGK1 pS203 | ||||
Low | 74 | 1.000 | ||
High | 105 | 1.760 (1.221–2.537) | 0.002 | |
PDHK1 pT338 | ||||
Low | 75 | 1.000 | ||
High | 104 | 1.595 (1.111–2.291) | 0.011 | |
STAD | Age (years) | |||
≤ 60 | 56 | 1.000 | ||
> 60 | 39 | 1.754 (1.144–2.689) | 0.010 | |
Gender | ||||
Male | 60 | 1.000 | ||
Female | 35 | 1.017 (0.660–1.567) | 0.938 | |
TNM staged | ||||
I/II | 24 | 1.000 | ||
III/IV | 69 | 2.590 (1.536–4.365) | < 0.001 | |
PGK1 pS203 | ||||
Low | 51 | 1.000 | ||
High | 44 | 1.797 (1.173–2.752) | 0.007 | |
PDHK1 pT338 | ||||
Low | 49 | 1.000 | ||
High | 46 | 1.694 (1.105–2.596) | 0.016 | |
ESCA | Age (years) | |||
≤ 60 | 112 | 1.000 | ||
> 60 | 102 | 1.869 (1.300–2.686) | 0.001 | |
Gender | ||||
Male | 176 | 1.000 | ||
Female | 38 | 1.127 (0.709–1.789) | 0.614 | |
TNM stage | ||||
I/II | 98 | 1.000 | ||
III/IV | 116 | 6.447 (4.139–10.043) | < 0.001 | |
PGK1 pS203 | ||||
Low | 103 | 1.000 | ||
High | 111 | 1.669 (1.157–2.406) | 0.006 | |
PDHK1 pT338 | ||||
Low | 94 | 1.000 | ||
High | 120 | 1.763 (1.213–2.563) | 0.003 |
BRCA breast carcinoma, LIHC liver hepatocellular carcinoma, LUAD lung adenocarcinoma, STAD stomach adenocarcinoma, ESCA esophageal carcinoma, HR hazard ratio, 95% CI 95% confidence interval, TNBC triple-negative breast cancer, PGK1 pS203 phosphorylated phosphoglycerate kinase 1 (PGK1) S203, PDHK1 pT338 phosphorylated phosphorylate pyruvate dehydrogenase kinase 1 (PDHK1) T338
aThe data of TNBC in BRCA were available in 133 patients
bThe data of TNM stage in BRCA were available in 143 patients
cThe data of TNM stage in LIHC were available in 177 patients
dThe data of TNM stage in STAD were available in 93 patients